HGH 191AA (Somatropin)

HGH 191AA (Somatropin) is a recombinant form of human growth hormone with the same 191–amino acid sequence as endogenous GH. In regulated medical practice, it is used in specific, guideline-defined contexts such as certain forms of growth hormone deficiency and related pediatric and adult conditions.

Outside those settings, somatropin is often discussed in performance, body composition, and "anti-aging" narratives. Many such uses sit outside labeled indications and may not align with local regulations or consensus guidelines.

Somatropin binds to growth hormone receptors in multiple tissues, triggering downstream signaling cascades that influence growth, metabolism, and body composition. High-level effects can include:

• Stimulating production of insulin-like growth factor 1 (IGF-1), particularly in the liver
• Modulating protein, carbohydrate, and lipid metabolism
• Influencing linear growth in children and contributing to body composition changes in adults

The net impact of GH/IGF-1 signaling depends on dose, duration, age, baseline endocrine status, and coexisting conditions.

In approved medical use, somatropin may be indicated for specific growth hormone–related diagnoses such as pediatric GH deficiency, certain genetic or syndromic conditions, and adult GH deficiency as defined by local regulators and guidelines. Exact indications and eligibility criteria are product- and jurisdiction-specific.

In parallel, somatropin appears in non-approved contexts, including athletic or aesthetic discussions. These uses raise ethical, legal, and safety questions and should not be inferred as endorsed by high-level educational content like this.

Somatropin sits in S2.2.3 of the WADA Prohibited List, the sub-section that also captures long-acting GH analogues (lonapegsomatropin, somapacitan, somatrogon) and GH fragments such as AOD-9604 and hGH 176-191. It is a non-Specified Substance, prohibited year-round, and a therapeutic use exemption for adult GH deficiency is granted only against documented endocrine diagnosis.

Why hGH cases are rare relative to suspected use. Two validated approaches exist, and both have hard limits:

• The isoforms test exploits the fact that recombinant hGH is pure 22 kDa protein while endogenous secretion is a mixture of isoforms, so injection skews the 22 kDa ratio. It is specific but short-lived — roughly "12-24 h after the last GH dose" (Baumann, Endocr Rev 2012). In a controlled two-week low-dose administration study the isoform test flagged participants only 1.5-3 hours after an injection (Lehtihet et al., Drug Test Anal 2019).

• The biomarkers test measures IGF-1 and the type III collagen propeptide P-III-NP, which rise dose-dependently under GH and decay more slowly — a window of one to two weeks, at the cost of specificity and dependence on age and sex (Baumann 2012). Lehtihet's group found that tracking IGF-1 and P-III-NP against each athlete's own longitudinal baseline identified 88% of dosed participants, versus one participant using the population-based GH-2000 decision limit.

That gap is why several hGH sanctions arise from investigations rather than screening. Vahe Aivazian, a masters cyclist, accepted a four-year USADA sanction beginning 7 April 2021 for possession and use of ten substances including "Somatropin (hGH)," alongside ipamorelin, CJC-1295, GHRP-6 and IGF-1; he signed the acceptance the day before his arbitration hearing was to begin (USADA announcement). Possession alone was sufficient — no analytical finding for hGH was needed.

Reported side effects of GH therapy can include fluid retention, joint or muscle pain, carpal tunnel–like symptoms, and changes in glucose metabolism. Injection-site reactions and headaches are also described.

Longer-term and higher-dose exposure raises additional questions, including potential impacts on cardiovascular risk, insulin resistance, and tumor biology, particularly in individuals with pre-existing risk factors. These issues are complex and are best navigated under the supervision of clinicians familiar with current evidence and guidelines.

Somatropin (HGH) is identical to human growth hormone. Dosing is highly individual and indication-specific.

Unit Conversion: 1 mg of Somatropin is approximately 3 IU. High doses (>4 IU) significantly increase risk of insulin resistance and water retention.

Somatropin reaches patients as several distinct product families rather than one drug. Approved formulations include two-chamber cartridge pens that mix diluent and lyophilized powder at the moment of use, prefilled disposable pens, and conventional vials for reconstitution. They differ in concentration, in whether the device is reusable, and in which indications each brand carries — approved indication lists are per-product, not class-wide (Genotropin label, DailyMed).

Two combination questions come up repeatedly. The first is somatropin alongside GH secretagogues such as ipamorelin or CJC-1295: the two act at different points — one supplies the hormone, the other asks the pituitary for it — and adding a secretagogue to exogenous GH does not evade the feedback suppression that exogenous GH itself causes. The second is somatropin with insulin, which is pharmacologically adversarial: GH is a counter-regulatory hormone to insulin, and the label already directs prescribers to monitor glucose in all patients and to expect antihyperglycemic doses to need adjustment.

Decades of research have explored GH therapy in growth hormone deficiency, certain syndromic disorders, and selected adult populations. Outcomes of interest include growth velocity, body composition, metabolic markers, and quality of life.

There is also a body of work examining GH and IGF-1 in aging, performance, and cardiometabolic risk, though findings are nuanced and sometimes conflicting. High-level summaries cannot replace careful reading of primary literature and guideline documents when making clinical or personal decisions.

For deeper dives on this peptide, see:

• HGH 191AA (Somatropin) benefits and areas of interest
• HGH 191AA (Somatropin) side effects and safety context
• HGH 191AA (Somatropin) dosing concepts (educational)
• HGH 191AA (Somatropin) research and evidence overview

Is somatropin the same thing as "HGH"? Yes. Somatropin is recombinant human growth hormone with the identical 191-amino-acid sequence as the pituitary hormone, which is where the "191AA" label comes from. It is the hormone itself, not a compound that prompts the body to release more of its own.

Is it FDA-approved? Yes, for defined conditions. Approved indications for Genotropin, a representative product, cover pediatric growth failure due to growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome, and idiopathic short stature, plus adult-onset or childhood-onset growth hormone deficiency in adults (DailyMed). Anti-aging and athletic use appear nowhere on that list.

Does growth hormone work as an anti-aging therapy? The randomized evidence says no. A systematic review of 18 study populations of healthy elderly adults found fat mass fell about 2.1 kg and lean mass rose about 2.1 kg, with no change in body weight or bone density — and significantly more soft-tissue edema, arthralgia, carpal tunnel syndrome, and gynecomastia, plus somewhat more diabetes and impaired fasting glucose. The authors concluded GH cannot be recommended as an anti-aging therapy (PMID 17227934).

Does it improve athletic performance? Not in the trials. A review of 27 randomized study samples in young, fit participants (mean age 27) again found roughly 2.1 kg more lean body mass, but strength and exercise capacity did not improve; exercise lactate was higher in two of three studies measuring it, and edema and fatigue were more common (PMID 18347346). A change on a body-composition scan is not the same as a change in what someone can do.

How is somatropin dosed in approved use? By indication and by response. The weekly amount is divided across six or seven subcutaneous injections, pediatric dosing is weight-based, and adult dosing is adjusted against IGF-I concentrations rather than fixed. Details are on the dosing page.